Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM8 | O00222 | 4/20 | 0.55 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.55 |
| ▸ | GRM6 | O15303 | 2/20 | 0.46 |
| ▸ | KIF11 | P52732 | 4/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL57237 | 0.86 | GRM8 (0.61) | GRM8GRM4GRM6KIF11 | |
| SCHEMBL56895 | 0.85 | GRM8 (0.50) | GRM8GRM4GRM6KIF11 | |
| SCHEMBL56486 | 0.84 | BTN3A1 (0.51) | GRM8GRM4GRM6KIF11 | |
| SCHEMBL56602 | 0.84 | GRM8 (0.49) | GRM8GRM4GRM6KIF11 | |
| SCHEMBL56062 | 0.84 | GRM4 (0.52) | GRM8GRM4GRM6KIF11 | |
| SCHEMBL27883029 | 0.82 | GRM8 (0.48) | GRM8GRM4GRM6KIF11PTPN1 | |
| SCHEMBL56052 | 0.81 | GRM8 (0.47) | GRM8GRM4GRM6KIF11PTPN1 | |
| SCHEMBL56728 | 0.81 | GRM4 (0.46) | GRM8GRM4GRM6KIF11ALDH1A1 | |
| SCHEMBL56830 | 0.80 | GRM8 (0.56) | GRM8GRM4GRM6ALDH1A1 | |
| SCHEMBL56342 | 0.76 | POLB (0.50) | GRM8GRM4GRM6KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008137446-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY DISEASE | TRUSTEES OF BOSTON UNIVERSITY (US) | 2008-11-13 | — | — | WO | claimed |
| US-8129557-B2 | Phosphonic acid diester derivative and method for producing thereof | Nagai, Kazuhiro (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20090163725-A1 | PHOSPHONIC ACID DIESTER DERIVATIVE AND METHOD FOR PRODUCING THEREOF | HIRATAKE, GOU (JP) | 2009-06-25 | — | — | US | disclosed |
| WO-2008137446-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY DISEASE | TRUSTEES OF BOSTON UNIVERSITY (US) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163725-A1 | PHOSPHONIC ACID DIESTER DERIVATIVE AND METHOD FOR PRODUCING THEREOF | PPA1, G6PD, PHOSPHO1 | GRM8 4595/4885GRM4 4122/4885GRM6 3489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.